Simvastatin therapy in climacteric women with atherogenic dyslipoproteinemias
The study aimed to assess real-world clinical practice effectiveness and safety of simvastatin therapy in climacteric women. A prospective cohort study included 82post-menopausal women with lipid-lowering therapy indications; median age 56,5 (52,0-60,0) years. Simvastatin therapy lasted for one year...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2008-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1540 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The study aimed to assess real-world clinical practice effectiveness and safety of simvastatin therapy in climacteric women. A prospective cohort study included 82post-menopausal women with lipid-lowering therapy indications; median age 56,5 (52,0-60,0) years. Simvastatin therapy lasted for one year. After three months of the treatment, total cholesterol (TCH) level significantly reduced, due to decreased low-density lipoprotein (LDL) CH, athemgenicity index decreased, and high to low-density lipoprotein CH ratio increased. Levels of triglycerides and high-density lipoprotein CH remained the same, as well as liver enzyme activity. Neuro-vegetative symptoms of climacteric syndrome become less manifested. Ln climacteric women, long-term simvastatin therapy controlled lipid metabolism effectively and safely. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |